362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

Autor: Emmett Schmidt, Jonathan Thompson, Michael Chisamore, James Spicer, Åslaug Helland, Edurne Arriola, Manuel Dómine Gomez, Jose Manuel Trigo Perez, Ana Laura Ortega Granados, Noelly Madeleine, Austin Rayford, Katherine Lorens, Abdul Siddiqui, Hani Gabra, Jaya Nautiyal, David Micklem, James Lorens
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Druh dokumentu: article
ISSN: 2051-1426
DOI: 10.1136/jitc-2020-SITC2020.0362
Databáze: Directory of Open Access Journals